Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

[Low molecular weight heparin decreases thrombosis risk in patients receiving chemotherapy for cancer].

Heller S, Krause M.

Strahlenther Onkol. 2013 Jun;189(6):514-5. doi: 10.1007/s00066-013-0352-z. German. No abstract available.

PMID:
23609135
2.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

3.

Letters on management of ischemic stroke.

Porat G.

Am Fam Physician. 2012 Sep 15;86(6):492. No abstract available.

4.

Preventing blood clots after knee arthroscopy.

[No authors listed]

Ann Intern Med. 2008 Jul 15;149(2):I40. No abstract available.

PMID:
18626044
5.

Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trial.

Camporese G, Bernardi E, Prandoni P, Noventa F, Verlato F, Simioni P, Ntita K, Salmistraro G, Frangos C, Rossi F, Cordova R, Franz F, Zucchetta P, Kontothanassis D, Andreozzi GM; KANT (Knee Arthroscopy Nadroparin Thromboprophylaxis) Study Group.

Ann Intern Med. 2008 Jul 15;149(2):73-82.

PMID:
18626046
6.

Semuloparin helps prevent thromboembolic events in patients receiving chemotherapy.

[No authors listed]

Oncology (Williston Park). 2012 Mar;26(3):258, 264. No abstract available.

7.

Is low-molecular-weight heparin suitable in all patients undergoing knee arthroplasty?

Geerts W.

Ann Intern Med. 2008 Nov 4;149(9):687; author reply 687-8. No abstract available.

PMID:
18981493
8.

Thromboprophylaxis in knee arthroscopy patients: revisiting values and preferences.

Hull RD.

Ann Intern Med. 2008 Jul 15;149(2):137-9. No abstract available.

PMID:
18626053
9.

Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.

Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A.

Acta Oncol. 2014 Sep;53(9):1230-7. doi: 10.3109/0284186X.2014.934397. Epub 2014 Aug 27. Review.

PMID:
25162954
10.

[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].

[No authors listed]

MMW Fortschr Med. 2003 Jun 12;145(24):56. German. No abstract available.

PMID:
12866309
11.

PEP trial. Pulmonary Embolism Prevention.

Mahé I, Bergmann JF, Mahé E, Caulin C.

Lancet. 2000 Jul 15;356(9225):248; author reply 250-1. No abstract available.

PMID:
10963217
12.

Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.

Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK; TOPIC Investigators.

Clin Appl Thromb Hemost. 2012 Mar-Apr;18(2):159-65. doi: 10.1177/1076029611433769. Epub 2012 Jan 23.

PMID:
22275397
13.

Low molecular weight heparins: prophylaxis of venous thromboembolism in surgical patients.

Kakkar VV.

Semin Hematol. 1997 Oct;34(4 Suppl 4):9-19. Review. No abstract available.

PMID:
9399405
15.

The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm.

Chen YW, Khorana AA.

Am J Hematol. 2017 Jun;92(6):E101-E103. doi: 10.1002/ajh.24712. Epub 2017 May 2. No abstract available.

PMID:
28263404
16.

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, Samama CM.

Chest. 2012 Feb;141(2 Suppl):e227S-e277S. doi: 10.1378/chest.11-2297. Erratum in: Chest. 2012 May;141(5):1369.

17.

[Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins].

Kreher S, Riess H.

Internist (Berl). 2014 Apr;55(4):448-54. doi: 10.1007/s00108-014-3476-z. German.

PMID:
24599489
18.

Thromboprophylaxis in patients receiving chemotherapy.

Bachmeyer C, Pellen JC.

N Engl J Med. 2012 May 10;366(19):1839; author reply 1839-40. doi: 10.1056/NEJMc1203094#SA1. No abstract available.

PMID:
22571208
19.

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH.

Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296.

20.

An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.

Schellong SM, Haas S, Greinacher A, Schwanebeck U, Sieder C, Abletshauser C, Bramlage P, Riess H.

Expert Opin Pharmacother. 2010 Dec;11(18):2953-61. doi: 10.1517/14656566.2010.521498. Epub 2010 Oct 18.

PMID:
20950224

Supplemental Content

Support Center